Companies › Kumquat Biosciences
5 active drug programs in 8 registered trials: 7 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KQB198 | – | Phase 2 | GIST - Gastrointestinal Stromal Tumor; Solid Tumor, Adult; Hematologic Malignancies; KRAS G12C Mutation | Dec 2026 |
| KQB548 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumor Malignancies | Mar 2027 |
| KQB168 | – | Phase 1 | Solid Tumor Malignancies | Nov 2027 |
| KQB365 | – | Phase 1 | KRAS G12C Mutation | Jun 2029 |
| KQB368 | – | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06507306 | KQB198 | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT06645886 | KQB198 | Phase 1 | Hematologic Malignancies | Oncology | Mar 2027 |
| NCT07207707 | KQB548 | Phase 1 | Solid Tumor Malignancies | Oncology | Mar 2027 |
| NCT07406633 | KQB198 | Phase 2 | GIST - Gastrointestinal Stromal Tumor | Oncology | Oct 2027 |
| NCT06994806 | KQB168 | Phase 1 | Solid Tumor Malignancies | Oncology | Nov 2027 |
| NCT06720987 | KQB365 | Phase 1 | KRAS G12C Mutation | Oncology | Jun 2029 |
| NCT06720987 | KQB198 | Phase 1 | KRAS G12C Mutation | Oncology | Jun 2029 |
| NCT07542704 | KQB368 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2029 |
Genfleet Therapeutics (Shanghai) Ranok Therapeutics (Hangzhou) Vividion Therapeutics Jacobio Pharmaceuticals Erasca
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.